Copyright
©2014 Baishideng Publishing Group Co., Limited. All rights reserved.
Cost-effectiveness of Fluorine-18-Fluorodeoxyglucose positron emission tomography in tumours other than lung cancer: A systematic review
Salvatore Annunziata, Carmelo Caldarella, Institute of Nuclear Medicine, Catholic University of the Sacred Heart, 00168 Rome, Italy
Giorgio Treglia, Department of Nuclear Medicine and PET/CT Center, Oncology Institute of Southern Switzerland, 6500 Bellinzona, Switzerland
Author contributions: All authors contributed to the manuscript.
Correspondence to: Salvatore Annunziata, MD, Institute of Nuclear Medicine, Catholic University of the Sacred Heart, Largo Gemelli 8, 00168 Rome, Italy. salvatoreannunziata@live.it
Telephone: +39-63-0154978 Fax: +39-63-013745
Received: November 2, 2013
Revised: December 31, 2013
Accepted: February 16, 2014
Published online: March 28, 2014
Processing time: 166 Days and 12.5 Hours
Revised: December 31, 2013
Accepted: February 16, 2014
Published online: March 28, 2014
Processing time: 166 Days and 12.5 Hours
Core Tip
Core tip: Evidence based data about the cost-effectiveness of Fluorine-18-Fluorodeoxyglucose positron emission tomography (FDG-PET) or PET/computed tomography (PET/CT) in lung cancer already exist. The aim of our study is to systematically review published data on the cost-effectiveness of FDG-PET or PET/CT in tumours other than lung cancer.